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A B S T R A C T
BACKGROUND AND PURPOSE
While sensitive to internal carotid artery (ICA) occlusion, carotid ultrasound can produce
false-positive results. CT angiography (CTA) has a high specificity for ICA occlusion and
is safer and cheaper than catheter angiography, although less accurate. We determined
the cost-effectiveness of CTA versus catheter angiography for confirming an ICA occlusion
first suggested by carotid ultrasound.
METHODS
A Markov decision-analytic model was constructed to estimate the cost-effectiveness of
CTA compared with catheter angiography in a hypothetical cohort of symptomatic patients
with a screening examination consistent with an ICA occlusion. Costs in 2004 dollars were
estimated from Medicare reimbursement. Effectiveness was measured in quality-adjusted
life years.
RESULTS
The 2-year cost in the CTA scenario was $9,178, and for catheter angiography, $11,531,
consistent with a $2,353 cost-savings per person for CTA. CTA resulted in accrual of 1.83
quality-adjusted life years while catheter angiography resulted in 1.82 quality-adjusted
life years. CTA was less costly and marginally more effective than catheter angiography.
In sensitivity analyses, when CTA sensitivity and specificity were allowed to vary across a
plausible range, CTA remained cost-effective.
CONCLUSIONS
After screening examination has suggested an ICA occlusion, confirmatory testing with
CTA provides similar effectiveness to catheter angiography and is less costly.
Introduction
Carotid endarterectomy (CEA) is superior to medical therapy
in prevention of stroke in patients with symptomatic severe
carotid artery disease.1,2 Initial screening for carotid disease
in stroke patients is commonly performed with carotid ultra-
sound (CUS).3 In 15% of symptomatic patients, CUS suggests
an internal carotid artery (ICA) occlusion. However, because
of technical limitations of CUS, the artery is actually patent in
up to 14% of these cases.4 Therefore, when a CUS suggests an
ICA occlusion, further testing is often deemed necessary.
The second test selected for confirmation of a suspected oc-
clusion is often intra-arterial conventional angiography (CA)
or CT angiography (CTA). These two tests, CA and CTA are
not as flow-dependent as CUS and MR angiography (MRA),5-7
and therefore are more accurate in differentiating between a
complete occlusion and severe stenosis.8,9 CA is considered
the reference standard for assessing the degree of ICA steno-
sis. CA carries with it a risk of stroke and is expensive, while
CTA is safer and less costly than CA, but is less accurate. We
therefore performed a cost-utility analysis to determine the cost-




A decision analytic model was constructed to consider the
use of two alternative strategies, CTA and CA, to confirm
the diagnosis of an ICA occlusion suspected based on CUS
in a hypothetical cohort of symptomatic patients. Four possi-
ble outcomes were considered: death from the diagnostic test,
stroke from the diagnostic test, stroke by 2 years, and death by
2 years. Two-years was selected for the time-horizon as the risk
of stroke for those with a severe stenosis who undergo CEA
approximates those treated medically after 2-3 years.10 Fur-
thermore, estimates of probabilities beyond 2 years are less
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Fig 1. Markov model.
well-established. Long-term outcomes were modeled using
Markov models. Markov processes use simulation techniques
to evaluate a hypothetical cohort of patients’ prognoses given
repeated exposure to a particular health risk. Each hypothet-
ical patient who did not have a diagnostic test-related stroke
was modeled to start in the well state. He/she could transition
from well to stroke, or dead as dictated by monthly Markov
transition probabilities. A diagram of the Markov model in iso-
lation is shown in Figure 1. Model inputs were derived from
the literature. All estimates derived from the literature were ex-
Table 1. List of Probabilities, Utilities, and Costs for the Reference Cases, and Ranges Used for Sensitivity Analyses
Reference Case Lower Range Tested Upper Range Tested
Probability of ICA occlusion .89 (33) .86 (4) .97 (11)
CTA sensitivity .97 (13) .92 (13) 1.0 (13)
CTA specificity .99 (13) .98 (13) 1.0 (13)
Stroke CTA 0 - -
CA sensitivity and specificity 1.0 - -
Death CTA .000006 (16) .000004 (35) .0005
Stroke CA .01 (15) .0014 (36) .015
Death CA .0006 (15, 36) .0002 .0010
Monthly probability of death after ICA occlusion .0056 (14) .004 .007
Monthly probability of death 70-99% stenosis .0048 (1) .003 .006
Monthly probability of stroke after ICA occlusion .0048 (14) .003 .006
Monthly probability of stroke after ICA occlusion with CEA .0053 (14) .004 .007
Monthly probability of stroke 70-99% stenosis with CEA .0056 (1) .004 .02
Monthly probability of stroke 70-99% stenosis without CEA .013 (1) .005 .02
Utility of stroke state .6 (17) .0 (17) .7 (17)
Cost CEA $16,304 (37) $10,768 (18) $20,000
Cost CTA $842 (38, 39) $500 $1,500
Cost CA $3,042 (38, 39) $2,000 $4,000
Cost stroke death $19,295 (19, 20) $10,000 $30,000
Cost of stroke hospitalization $10,726 (19) $5000 $15,000
Monthly cost of stroke $2,170 (20) $1,000 $3,000
Cost of death from CTA $5,000∗ $2,500 $10,000
∗Estimated.




plored in a one-way sensitivity analysis across a plausible range
of values, as shown in Table 1. Two-way sensitivity analyses
were also conducted with both CTA sensitivity and specificity
and several key variables: probability of ICA occlusion at the
time of the test, probability of stroke from CA, and the utility of
stroke. A “worst-case” scenario analysis was then performed bi-
asing the analysis against CTA. This used the costs, sensitivities,
specificities, and complications found in Table 1, which were fa-
voring CA and disadvantaging CTA: the lowest values for CTA
sensitivity and specificity were used, while the highest costs and
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complications for CTA and the lowest values for complications
and costs for CA were used. We further explored the effect of
biasing variables on the model results by only partially bias-
ing the analysis against CTA. First all CTA variables that dis-
advantaged CTA were used. Separately we used all CA vari-
ables that favored CA. As contrast-enhanced MRA is often used
as a screening test for ICA disease, the analysis was repeated
substituting the accuracy of contrast-enhanced MRA for that of
CUS. The decision tree was analyzed using Data 4.0 (TreeAge
software, Inc, Williamstown, MA).
Baseline Probability of ICA Occlusion
The positive predictive value of carotid ultrasound in detect-
ing a complete ICA occlusion was estimated to be .97.11 This
value was used for the true baseline estimate of ICA occlusion
in those undergoing CA or CTA. The analysis was repeated
assuming contrast-enhanced MRA was used to screen individ-
uals for carotid disease using a baseline prevalence equal to the
positive predictive value of contrast-enhanced MRA for ICA
occlusion, .93.12 The value of the probability of occlusion was
allowed to vary in sensitivity analyses (see Table 1). It was as-
sumed that a 0-69% stenosis and complete occlusion are never
mistaken for one another by any of the diagnostic tests.
Accuracy of CTA
Koelemay et al. 13 systematically reviewed the literature analyz-
ing the aggregated sensitivity and specificity of CTA. Sensitivity
and specificity values were obtained from this study and were
allowed to vary in sensitivity analysis through the range of their
99% confidence intervals.
Risks
Estimates of stroke and mortality probabilities can be found
in Table 1. Monthly probabilities of stroke were estimated
from the North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET) 1 for patients with 70-99% stenoses (in-
corporating strokes and deaths as a result of CEA where appli-
cable), and from an analysis of prospective and retrospective
series for those with complete occlusions.14 Two-year mortality
for CEA and non-CEA groups was not significantly different in
the NASCET study and thus were averaged together. It was as-
sumed that there was no benefit conferred by CEA in patients
with complete occlusions and that this surgery would yield a
1% higher stroke risk above baseline when performed in those
with a complete occlusion.
For the reference case analysis, a 1% stroke risk and a .06%
death risk associated with CA were estimated from data pooled
from eight prospective studies.15 It was assumed based on the
literature that the only significant complication from CTA was
death related to contrast administration. This was estimated to
occur in .0006% of contrast injections.16
Outcomes
Utilities are measures between 0, representing death, and 1,
representing perfect health, which can be assigned to a health
state in order to account for the relative adverse effect the condi-
tion has on quality of life. Quality-adjusted life years (QALYs)
were calculated by multiplying utilities by life-years spent in
that health state. Utility measures were estimated from the lit-
erature. The utility value used for stroke, .6, was obtained from
healthy subjects using the standard gamble approach,17 but this
value was allowed to vary widely in sensitivity analyses.17
Costs
A societal perspective, which considers costs regardless of the
identity of the payer, was taken. All costs were converted to
2004 US dollars and are found in Table 1. The cost of CA and
CTA were estimated from Medicare fee schedules and included
technical and physician components. The cost of CEA, monthly
cost of stroke, and cost of death from stroke were estimated from
studies where Medicare reimbursement was used.18-20 Costs,
calculated using the cost-to-charge ratio or Medicare allowable
payments, included hospitalization, physician time, rehabilita-
tion, durable medical equipment, and skilled nursing home
care.20 Nonskilled nursing home care and outpatient medica-
tions were also considered.20
Results
The average patient undergoing CTA experienced 1.83 QALYs
at a cost of $9,178; while those undergoing CA experienced 1.82
QALYs at a cost of $11,531, resulting in an incremental cost
of $2,353 for CA. The cost-effectiveness of CTA was $5,012
and for CA was $6,322. Repeating the analysis assuming that
contrast-enhanced MRA was used for screening yielded simi-
lar results: CTA remained dominant over CA. Each variable
was allowed to vary in one-way sensitivity analysis using the
value ranges found in Table 1. The results of the analysis were
insensitive to these alterations, with the CTA strategy remain-
ing dominant over CA. Two-way sensitivity analyses performed
with CTA sensitivity and specificity and the key variables (prob-
ability of ICA occlusion at the time of the test, probability of
stroke from CA, and the utility of stroke) also supported CTA
as the preferred strategy throughout the ranges tested.
In the “worst case” scenario model, where the costs, sensi-
tivities, specificities, and complications were all biased against
CTA and in favor of CA, the incremental cost-effectiveness of
CTA was $690,225 suggesting that CTA was no longer cost-
effective compared with CA. CTA remained dominant over
CA in the two partially biased models.
Discussion
This cost-effectiveness analysis suggests that CTA is preferable
to CA to confirm a symptomatic carotid occlusion suspected
based on a screening ultrasound or MRA. Despite the supe-
rior sensitivity and specificity of CA in the model compared
with CTA, the greater cost of CA along with its higher rates
of complications shifts the advantage to CTA. In the scenario
with all model input variables biased against CTA and in fa-
vor of CA, the incremental cost-effectiveness of CTA was no
longer in a range considered to be cost-effective.21 The deci-
sion to pursue further diagnostic testing in a patient who is
suspected of having an ICA occlusion is a tradeoff between po-
tential complications of the confirmatory test and the need to
identify an operable ICA stenosis. Despite CTA’s inferior accu-
racy, its lower complication rate and lower cost compared with
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CA resulted in a favorable cost-effectiveness ratio in almost all
scenarios tested.
For each 100 patients who receive a CTA in place of a CA
for evaluation of a carotid occlusion, over $235,000 is saved.
Although the difference in total costs between the tests is quite
large, the difference in outcomes for the two diagnostic strate-
gies compared in this analysis is small, suggesting that the model
results are largely being driven by the relative costs rather than
the relative effectiveness. Nonetheless, sensitivity analyses in-
volving both cost and effectiveness variables show that alter-
ations in key probabilities across plausible ranges do not alter
the superior cost-effectiveness of CTA in one- and two-way
sensitivity analyses, supporting the robustness of the model.
Furthermore, omitting CA-related TIA, hematoma, and infec-
tion from the model biased the analysis in favor of CA. If these
unmodeled variables were to be considered, in addition to pa-
tient preferences, the support in favor of CTA would become
even stronger.22 Use of a two-year time horizon, rather than
modeling until death, also biased the model in favor of CA.
Despite these numerous biases in favor of CA, CTA remained
cost-effective compared with CA through all scenarios tested.
Previous cost-effectiveness analyses related to carotid dis-
ease have not considered CTA.23-26 Furthermore, these studies
have dealt with overall strategies for screening for surgical ICA
lesions, rather than addressing more focused questions such as
the current analysis. Although CTA has limitations, such as dif-
ferentiating between a moderate and severe stenosis,27,28 there
have been many series showing that it is an accurate technology
for detecting occlusions.8,9,13 When selecting a test for carotid
artery evaluation, it is important to select the test based on the
specific question being asked.
A recent post-hoc meta-analysis suggested that endarterec-
tomy for the subset of severe stenoses regarded as near-
occlusions may not be beneficial when assessing 5- and 8-year
outcomes.29,30 The validity of these types of subgroup analyses
and the statistical methods used are questionable.31 Nonethe-
less, the benefit measured at 1 and 3 years post-CEA in those
with near-occlusions is better established.30,32 Although there
is evidence that not all false-positive occlusions detected by
CUS or contrast-enhanced MRA can be attributed to near-
occlusions,4-6,33 the true proportion is unknown. Sensitivity
analysis addressed the impact of altering the benefit of CEA
in the severe stenosis group. As the monthly probability of
stroke in those who received CEA approached those who did
not, CTA remained more cost-effective than CA.
The true accuracy of CTA in detecting carotid artery occlu-
sions is unknown. Studies reporting its accuracy are likely from
centers with significant experience with CTA. The accuracy
of CTA in less experienced hands may not be so high, which
may limit the applicability of our results to centers proficient
in CTA performance and interpretation. The sensitivity and
specificity of CTA conditional on the ultrasound results may
also differ from the primary sensitivity and specificity of CTA.
The estimates of CTA sensitivity and specificity reported in the
literature may be subject to publication bias;34 however, the
concordance among many studies argues against this being a
major factor. As with any cost-utility analysis, the current results
are limited by the accuracy of the estimates used in the model.
To mitigate against this, we performed multiple sensitivity anal-
yses across a wide range of values, and included a “worst-case”
scenario model.
Conclusion
Given rising health care costs, cost-minimizing diagnostic strate-
gies need to be explored. This analysis suggests that CTA can be
used as a less expensive alternative to CA for confirmation of a
suspected ICA occlusion, without sacrificing patient outcome.
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